Harmony Biosciences targets $1B-$1.04B WAKIX revenue in 2026 while expanding late-stage CNS pipeline
Source: SeekingAlpha
2026-02-24 15:38:33 ET
More on Harmony Biosciences Holdings, Inc.
- Harmony Biosciences Holdings, Inc. (HRMY) Q4 2025 Earnings Call Transcript
- Harmony Biosciences Holdings, Inc. 2025 Q4 - Results - Earnings Call Presentation
- Harmony Biosciences Makes The Grade
- Harmony Biosciences Holdings, Inc. Non-GAAP EPS of $0.57 misses by $0.50, revenue of $243.78M beats by $3.46M
- Harmony Biosciences tumbles following Deutsche Bank, Truist downgrades
Read the full article on Seeking Alpha
For further details see:
Harmony Biosciences targets $1B–$1.04B WAKIX revenue in 2026 while expanding late-stage CNS pipeline
Harmony Biosciences Holdings Inc.
NASDAQ: HRMY
HRMY Trading
1.9% G/L:
$28.095 Last:
174,199 Volume:
$27.85 Open:
HRMY Latest News
February 24, 2026 07:30:00 am
Harmony Biosciences Reports Strong 2025 Financial Results and Reiterates 2026 Net Revenue Guidance of Over $1 Billion
HRMY Stock Data
$2,184,629,859
44,003,618
0.12%
112
N/A
Biotechnology & Life Sciences
Healthcare
US
Plymouth Meeting
